Loading
A phase 3 trial testing SHR-A1921 in ovarian cancer, now recruiting.
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06394492, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Randomised, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer. Planned enrolment is 440 participants (estimated). The study started in 2024-05-10 and primary completion is expected in 2026-05-31. No results have been posted on ClinicalTrials.gov.
Shares SHR-A1921, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A1921, Jiangsu Hengrui Pharmaceuticals.
Shares Platinum-resistant ovarian cancer, Jiangsu Hengrui Pharmaceuticals, Ovarian cancer.